ARTICLE | Clinical News

Zybrestat fosbretabulin regulatory update

December 19, 2011 8:00 AM UTC

OxiGene began a named-patient program to provide access to Zybrestat fosbretabulin to treat anaplastic thyroid cancer (ATC) in Canada and the EU, including Nordic countries and Switzerland. Azanta A/S (Hellerup, Denmark) will manage the program. OxiGene said it is seeking financing for a Phase III trial of Zybrestat in ATC, for which it hopes to begin next year. Last year, the company reported data from Phase II/III FACT trial to treat ATC in 80 patients that showed weekly Zybrestat plus carboplatin and paclitaxel missed the primary endpoint of a significantly higher median overall survival vs. chemotherapy alone (see BioCentury, Sept. 20, 2010). ...